trending Market Intelligence /marketintelligence/en/news-insights/trending/1q9t3LmedwDKpkYpIUHgPA2 content esgSubNav
In This List

Merck's Alzheimer drug study triggers $10M milestone payment to Bionomics

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Merck's Alzheimer drug study triggers $10M milestone payment to Bionomics

Merck & Co. Inc. initiated a clinical trial for a novel cognition drug candidate, triggering a $10 million milestone payment to Bionomics Ltd.

Merck and Bionomics entered a research and license agreement in June 2014 to develop candidates to treat cognitive dysfunction associated with Alzheimer's disease.

Under the agreement, Merck is responsible for funding all early-stage and clinical development of any candidate within the collaboration and worldwide commercialization.

Meanwhile, Bionomics received $20 million in upfront payments and is eligible for up to an additional $506 million for predefined research and clinical development milestones, plus eventual undisclosed royalties on any product sales.